Pharmacy No. 84. Delivery of medicines to your home and office.

The pharmacy is closed on Sundays and holidays.

Medicines

my basket

Apteka84.kz is an online pharmacy that offers its customers medicines, medicinal and decorative cosmetics, dietary supplements, vitamins, baby food, intimate products for adults, medical equipment and thousands of other medical and cosmetic products at low prices. All data presented on the Apteka84.kz website is for informational purposes only and is not a substitute for professional medical care. Apteka84.kz strongly recommends that you carefully read the instructions for use contained in each package of medicines and other products. If you currently have any symptoms of the disease, you should seek help from a doctor. You should always tell your doctor or pharmacist about all the medicines you take. If you feel you need further help, please consult your local pharmacist or contact our GP online or by telephone.

Febrofid 100 mg No. 20 tablet p.o.

APPROVED by the Order of the Chairman of the Committee for Control of Medical and Pharmaceutical Activities of the Ministry of Health and Social Development of the Republic of Kazakhstan Instructions for the medical use of the drug FEBROFIDE Trade name FEBROFIDE International non-proprietary name Ketoprofen Dosage form Film-coated tablets 100 mg Composition 1 tablet contains the active substance: ketoprofen 100 mg, auxiliary substances: microcrystalline cellulose, crospovidone, colloidal anhydrous silicon dioxide, magnesium stearate. shell composition (OPADRI II 33G32852 Yellow): hypromellose, lactose monohydrate, triacetin, macrogol 3000, quinoline yellow E 104, iron (III) oxide red E 172, iron (III) oxide yellow E 172, titanium dioxide E 171 Description Round tablets , with a biconvex surface, covered with a light yellow shell. Pharmacotherapeutic group Anti-inflammatory and antirheumatic drugs. Non-steroidal anti-inflammatory drugs. Propionic acid derivatives. Ketoprofen. ATC code M01AE03 Pharmacological properties Pharmacokinetics Absorption Ketoprofen is well absorbed from the gastrointestinal tract. After oral administration of a ketoprofen tablet at a dose of 100 mg, the maximum concentration in the blood plasma is achieved in approximately 60 - 90 minutes. The bioavailability of ketoprofen is approximately 90%. Food does not affect the overall bioavailability of ketoprofen. Distribution Ketoprofen is 99% bound to plasma proteins, mainly albumin. Ketoprofen penetrates into the synovial fluid and joint cavity: joint capsule, synovial membrane and periarticular tissue. Ketoprofen also penetrates into the cerebrospinal fluid and through the placental barrier. After repeated administration, ketoprofen does not accumulate in the body. Metabolism Ketoprofen is biotransformed in the liver, mainly by conjugation with glucuronic acid and partly by hydroxylation. Metabolites are pharmacologically inactive. Excretion Both ketoprofen and its metabolites are excreted mainly in the urine. After taking ketoprofen orally, approximately 75% to 90% of the dose is excreted in the urine after 5 days. Less than 1% of ketoprofen is excreted unchanged. Excretion in feces ranges from 1% to 8%. The half-life of ketoprofen is about 2 hours. Pharmacodynamics Febrofid, a derivative of phenylpropionic acid, belongs to the group of non-steroidal anti-inflammatory drugs. It has anti-inflammatory, analgesic, antipyretic and antiaggregation effects. The mechanism of its action is due to the inhibition of cyclooxygenase, the enzyme responsible for the synthesis of prostaglandins. Febrofid is also a bradykinin antagonist. Inhibits the synthesis of leukotrienes, reduces blood platelet aggregation, and has a stabilizing effect on lysosomal membranes. Indications for use In the complex therapy of inflammatory and inflammatory-degenerative and metabolic diseases of the joints (rheumatoid arthritis, osteoarthritis, spondyloarthritis, psoriatic arthritis, reactive arthritis, gouty arthritis, pseudogout, etc.) - extra-articular rheumatism: tenosynovitis, bursitis, capsulitis, etc. - pain syndrome of various etiologies: headache, migraine and migraine-like pain, toothache, algodismenorrhea, pain with bone metastases in patients with cancer; postoperative and post-traumatic pain; neuralgia, myalgia of various origins, sciatica. Method of administration and dosage Febrofid tablets are taken without chewing, with a sufficient amount of water, during meals or immediately after meals. Febrofid tablets 100 mg: prescribed 1-2 tablets per day, once or in two doses. For short-term symptomatic therapy: 1 tablet 3 times a day. The duration of treatment is determined by the doctor. Side effects Often: - dyspeptic symptoms, loss of appetite, nausea, vomiting, flatulence, abdominal pain, constipation Uncommon: - diarrhea, gastritis - headache, dizziness, drowsiness - skin rash Rarely: - hemorrhagic anemia, leukopenia - depression, insomnia, nervousness , paresthesia - blurred vision - tinnitus - stomatitis, gastric and duodenal ulcers - hepatitis, increased levels of transaminases and bilirubin - weight gain - anaphylactic shock - bronchospasm, attack of bronchial asthma Very rarely: - exacerbation of colitis and Crohn's disease, gastrointestinal tract intestinal bleeding - impaired liver function - acute renal failure, tubulointerstitial nephritis - hypernatremia, hyperkalemia - agranulocytosis, thrombocytopenia - seizures - heart failure - arterial hypertension - rhinitis - photosensitivity, Quincke's edema, bullous rash, including Stevens-Johnson syndrome, toxic epidermal necrolysis Contraindications - individual hypersensitivity to ketoprofen, aspirin or other non-steroidal anti-inflammatory drug (history of asthma, bronchospasm, urticaria or rhinitis associated with taking acetylsalicylic acid) - severe heart failure - gastrointestinal diseases in the acute phase (gastritis, peptic ulcer stomach, a history of gastrointestinal bleeding, formation or perforation of ulcers) - bleeding (gastrointestinal, cerebrovascular or other active bleeding) - bleeding tendency - severe liver or kidney failure - blood disorders (leukopenia, thrombocytopenia , hemocoagulation disorders) - pregnancy and lactation - childhood and adolescence up to 18 years of age Drug interactions Undesirable combinations With other NSAIDs, including salicylates in high doses: simultaneous use of several NSAIDs due to a synergistic effect increases the risk of gastrointestinal bleeding and ulcers. With anticoagulants: ketoprofen, like other NSAIDs, can enhance the effect of anticoagulants such as warfarin due to a high degree of binding to plasma proteins, inhibition of platelet aggregation and damage to the gastrointestinal mucosa. If simultaneous use is necessary, careful monitoring of the patient's condition and regular monitoring of laboratory parameters is necessary. With glucocorticosteroids: with simultaneous use, the risk of ulcerative lesions of the gastrointestinal tract and bleeding increases. With lithium preparations: NSAIDs increase the concentration of lithium in the blood plasma up to toxic levels, and therefore this indicator must be monitored when used simultaneously with ketoprofen, changing the dosage, and also after discontinuation of NSAIDs. With methotrexate in high doses (15 mg/week or more): the hematological toxicity of methotrexate may increase due to a decrease in its renal clearance when used simultaneously with NSAIDs. Combinations requiring caution With diuretics, angiotensin-converting enzyme (ACE) inhibitors, aminoglycoside antibiotics, angiotensin-II receptor antagonists: simultaneous use with NSAIDs is associated with the risk of developing acute renal failure in dehydrated patients (decreased glomerular filtration rate due to decreased synthesis of prostaglandins). When used concomitantly, NSAIDs may reduce the antihypertensive effect of some drugs. When using ketoprofen and diuretics simultaneously, it is necessary to ensure that the patient has no signs of dehydration, and also monitor renal function at the beginning of simultaneous use. With methotrexate in low doses (less than 15 mg/week): an increase in the hematological toxicity of methotrexate is possible due to a decrease in its renal clearance during simultaneous use with NSAIDs. A blood cell count is necessary when coadministration is initiated. In the presence of even mild renal dysfunction, as well as in elderly people, careful medical supervision is necessary. With pentoxifylline: there may be an increased risk of bleeding. Close clinical monitoring and regular checking of bleeding time (blood clotting time) is necessary. With zidovudine: there is a risk of increased toxicity to red blood cells due to effects on reticulocytes, with the development of severe anemia one week after starting NSAID use. It is necessary to conduct a general blood test with counting the number of reticulocytes 1 to 2 weeks after the start of NSAID therapy. With oral hypoglycemic agents: NSAIDs may enhance the hypoglycemic effect of sulfonylureas due to the displacement of sulfonylurea from sites of binding to plasma proteins. With beta-blockers: when used simultaneously with NSAIDs, the antihypertensive effect of beta-blockers may be reduced due to inhibition of prostaglandin synthesis. With cyclosporine and tacrolimus: NSAIDs may increase nephrotoxicity. During simultaneous use, it is necessary to monitor renal function. With thrombolytics: the risk of bleeding increases. The risk of bleeding from the gastrointestinal tract increases when used simultaneously with serotonin reuptake inhibitors (citalopram, fluoxetine, sertraline) and anticoagulants. With probenecid: an increase in the concentration of NSAIDs in the blood plasma is possible, which may be due to the inhibitory effect of probenecid on renal tubular secretion and/or conjugation with glucuronic acid; NSAID dose adjustment may be required. With cardiac glycosides: simultaneous use with NSAIDs may lead to an increase in the concentration of cardiac glycosides in the blood plasma. With mifepristone: due to the theoretical risk of changes in the effectiveness of mifepristone under the influence of prostaglandin synthesis inhibitors, NSAIDs should not be used earlier than 8-12 days after discontinuation of mifepristone. With quinolones: data obtained from experimental studies in animals indicate a high risk of developing seizures when NSAIDs are used concomitantly with quinolones in high doses. Febrofid may reduce the effectiveness of intrauterine contraceptives. Special instructions Undesirable side effects can be minimized by using the drug in the lowest effective dose with the minimum duration of use necessary to relieve pain. The risk of complications from the gastrointestinal tract increases in patients with a history of ulcerative lesions of the gastrointestinal tract, in elderly patients, with an increase in the dose of NSAIDs; therefore, the use of Febrofid in this category of patients should begin with the lowest recommended dose. For patients in the above categories, as well as patients who require simultaneous use of low doses of acetylsalicylic acid or other drugs that increase the risk of gastrointestinal complications, additional simultaneous use of gastroprotectors (misoprostol or proton pump blockers) is recommended. In patients simultaneously taking antiplatelet agents or anticoagulants, glucocorticosteroids, the risk of gastrointestinal bleeding also increases. Patients with gastrointestinal disorders or a history of gastrointestinal diseases should be under close medical supervision. If gastrointestinal bleeding or ulcerative lesions occur, use of the drug Febrofid should be discontinued. The drug Febrofid should be used with caution in patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease), since exacerbation of these diseases is possible. All NSAIDs can inhibit platelet aggregation and prolong bleeding time by inhibiting prostaglandin synthesis. In this regard, the use of Febrofid in patients simultaneously taking drugs that affect the hemostatic system, such as warfarin, coumarin derivatives and heparins, is not recommended. Persons with bronchial asthma and chronic rhinitis, chronic sinusitis and (or) nasal polyposis have an increased risk of allergies to acetylsalicylic acid and other NSAID drugs. Like other prostaglandin synthesis inhibitors, Febrofid may have side effects on the urinary system, which can lead to the development of glomerulonephritis, interstitial nephritis, papillary necrosis, nephrotic syndrome and acute renal failure. Caution should be exercised when using the drug in patients concomitantly using diuretics and patients who may develop hypovolemia, due to an increased risk of nephrotoxicity. As with the use of other NSAIDs, during therapy with Febrofid, a slight transient increase in the activity of liver enzymes may be observed. In elderly patients, monitoring of liver and kidney function is necessary. In case of a significant increase in the corresponding indicators, the use of the drug should be discontinued. Like other NSAIDs, ketoprofen can mask the symptoms of infectious diseases. If signs of infection or deterioration in health are detected while using the drug Febrofid, the patient should immediately consult a doctor. The drug can cause fluid retention in the body, so in patients with arterial hypertension, renal and/or heart failure, the drug should be used with extreme caution. If the condition worsens, use of the drug Febrofid should be discontinued. In patients with uncontrolled arterial hypertension, coronary artery disease, congestive heart failure, peripheral arterial disease and/or cerebrovascular disease, the drug should be used with caution. A similar approach is applicable to patients with risk factors for developing cardiovascular diseases (arterial hypertension, hyperlipidemia, diabetes mellitus, smoking). Caution should be exercised when prescribing Febrofid to patients with a history of cardiovascular disease, especially patients with heart failure, due to the possible risk of progression. Clinical studies and epidemiological data suggest that NSAIDs, especially in high doses and with long-term use, may lead to a small risk of acute myocardial infarction or stroke. There is insufficient data to exclude the risk of these events when using ketoprofen. Elderly patients are especially susceptible to adverse reactions when using NSAIDs, including the risk of life-threatening gastrointestinal bleeding and perforation, and decreased renal, liver, and cardiac function. When using the drug Febrofid in this category of patients, proper clinical monitoring is necessary. There is evidence of rare cases of skin reactions (such as exfoliative dermatitis, Steven-Johnson syndrome, toxic epidermal necrolysis) with the use of NSAIDs. At the first manifestations of a skin rash, damage to the mucous membranes or other signs of an allergic reaction, you should immediately stop taking Febrofid and consult a doctor. The use of Febrofid may adversely affect reproductive function in women and is not recommended for women planning pregnancy. In women who are unable to become pregnant or who are undergoing investigations for infertility, use of Febrofid should be discontinued. Febrofid should not be prescribed to patients with rare hereditary galactose intolerance, lactase deficiency (Lapp type) or glucose-galactose malabsorption syndrome. Features of the effect of the drug on the ability to drive a vehicle or operate potentially dangerous mechanisms In case of dizziness, spatial disorientation, drowsiness, you should not drive or operate potentially dangerous mechanisms. Overdose Symptoms: headache, drowsiness, nausea, vomiting, diarrhea, abdominal pain, hypotension or hypertension, respiratory depression, bleeding from the gastrointestinal tract, convulsions, acute renal failure. Treatment: symptomatic, there is no specific antidote. You must immediately stop using the drug. Gastric lavage and the use of activated carbon are indicated. Release form and packaging 10 tablets are placed in a blister pack made of polyvinyl dichloride film (PVDC) and aluminum foil. 1, 2 or 3 contour packages together with instructions for medical use in the state and Russian languages are placed in a cardboard box. Storage conditions Store in a dry place, protected from light, at a temperature not exceeding 25 °C. Shelf life: 1.5 years Do not use after the expiration date indicated on the package. Conditions for dispensing from pharmacies By prescription Name and country of the manufacturing organization Pharmaceutical JSC Production department in Nowa Demba, Poland Name and country of the owner of the registration certificate JSC "Khimpharm", Republic of Kazakhstan Name and country of the packaging organization Pharmaceutical JSC Production department in Nowa Demba, Poland Address organization that accepts claims from consumers on the quality of products (products) on the territory of the Republic of Kazakhstan and is responsible for post-registration monitoring of the safety of the drug Khimpharm JSC, Shymkent, Republic of Kazakhstan, 160019 st. Rashidova, 81 Phone number 7252 (561342) Fax number 7252 (561342) Email address